THERASIGHT® Ultraview Profiler assay is our state-of-the-art contribution to oncological precision medicine and the treatment of tumor diseases.
THERASIGHT® Ultraview Profiler assay refers to an all-in-one comprehensive molecular genetic test that not only analyzes the activity of all of the tumor’s more than 20.000 genes but that simultaneously registers therapeutically relevant mutations in cancer and tumor suppressor genes, too.
THERASIGHT® Ultraview Profiler comprises the following modules
- THERASIGHT® Expression Profiler /former PANTHER Test: PANTHER includes a complete transcriptome Transcriptome analysis (the measurement of the activity of all 20 000 human genes by gene expression array technology) complemented by quantitative PCR and immunohistochemistry of genes playing key roles in important signaling pathways. The THERASIGHT® Expression Profiler / PANTHER Report informs about the immune status of the tumor tissue including the responsiveness to checkpoint inhibitors, the sensitivity to various chemotherapeutic therapies as well as to natural compounds etc.
- THERASIGHT® Mutation Profiler: Comprehensive profiling of ~ 500 most important oncogenes and tumor suppressor genes for driver mutations by next-generation sequencing (NGS) supplemented by our Oncogene Knowledgebase Report, an up-to-date document of world-wide clinical trials and relevant drugs for the patient’s individual genetic fingerprint. The module includes an NTRK gene fusion analysis.
- Oncomine Tumor Mutation Load/Burden (TMB) Assay: Accurate assessment of TMB (Mutations/Mb) by large scale (1.65 Mb) NGS assay.
- Microsatellite Instability (MSI) assessed by NGS.
- DNA Mismatch Repair Enzyme Deficiency assessed by immunohistochemical (IHC) analysis of hMLH1, hMSH2, hMSH6, and hPMS2.
- Immune index assessed by immunohistochemistry. According to Joan M. C. Bull (2018). International Journal of Hyperthermia, 34:6, 840-852 is this index extremely important:
“The number of immune effector T-cells appears to be more important than a malignant tumor’s expression of a high number of tumor neoantigens , (or PDL-1 expression) . The number of effector T-cells in the tumor and its microenvironment is a major component of the “immune index” of a malignant tumor [4,92]. Data suggests that the immune index may be the most important predictor of tumor response to immunotherapies but also predicts response to chemotherapy, targeted therapy, and radiation therapy. Determining the numbers of cytotoxic CD8+, CD4+ and NK effector cells in the tumor or the tumor microenvironment unambiguously predicts whether tumors will respond to a checkpoint inhibitor.”
Fresh or cryopreserved tumor tissue is ideal for the high-resolution THERASIGHT® Ultraview Profiler assay technology. Fresh tumor cells from fresh pleural effusions or ascitic fluid are also suitable. Fortunately, formalin-fixed paraffin-embedded (FFPE) tissue is in general appropriate, too. Minuscule tissue samples (for instance, a few of slices skin from a punch biopsy or tissue collected in fine-needle aspiration biopsies) suffice. Detailed information can be found in our Specimen Collection and Transport Kits.
Duration of Testing
Turnaround time for our 500-gene panel is 10 working days. In Germany, the lead time for transporting cryopreserved tissue or tissue from pleural effusions and ascitic fluid is 24 hours before a planned procedure. We will contact the respective pathological institute to arrange for the FFPE tissue blocks. A single call will do, just ring us at 0211 4477 4388 (landline). We will take care of the entire logistic process for you.